Find and Pitch Jounalists, Get Your Story Covered

Tags: cisplatin,cisplatin-based chemotherapy,testicular cancer,cervical cancer,hearing loss breast cancer lung cancer multiple myeloma myeloma

	Profile	Recent Articles on Subject
1	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Sequencing in Advanced Urothelial Carcinoma - 17 days ago Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients - 11 months ago Adding Tucatinib to T-DM1 Shows PFS Benefit in HER2-Positive Breast Cancer - 11 months ago KEYNOTE-A18 Data Are 'Practice-Changing' for Cervical Cancer - 11 months ago Combining Immunotherapy and PARP Inhibition in Advanced Uterine Cancer - 12 months ago
2	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer - 2 months ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 2 months ago Trial Questions Role of Dual Immunotherapy in First-Line NSCLC - 3 months ago Celebrity Cancers Stoking Fear? Cisplatin Shortage Ends; Setback for Anti-TIGIT - 5 months ago Chemotherapy/ICI Combos Falter as Second-Line Treatment for Gastric Cancer - 8 months ago PD-1 Inhibitor Plus Chemotherapy Shows Promising Activity in Rare Lymphoma - 8 months ago First-Line Nivolumab Plus Chemo Approved for Bladder Cancer - 9 months ago Novel Therapy Promising for Radiation-Induced Oral Mucositis - 9 months ago Two Pembrolizumab Trials in Head and Neck Cancer Yield Divergent Results - 9 months ago New First-Line Option for Pancreatic Cancer Approved - 9 months ago Vaccine 'Promising' for Delaying Relapse in KRAS-Mutated Pancreatic Cancer, CRC - 10 months ago Atezolizumab Plus Carboplatin Boosts Survival in Metastatic TNBC - 11 months ago Neoadjuvant Cemiplimab Shows Potential as an Option for Cutaneous SCC - about 1 year ago Multi-Agent Treatment Offers Hope in Advanced or Recurrent Endometrial Cancer - about 1 year ago
3	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials - 2 months ago FDA Approves Axatilimab-csfr for cGVHD - 3 months ago Embracing a Precision Medicine Approach to KRAS G12C–Mutated Advanced NSCLC With Adagrasib - 8 months ago FDA Approves Tislelizumab-jsgr for Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy - 8 months ago Advancements in HER2+ Breast Cancer Treatment: Insights From the HER2CLIMB-02 Trial - 9 months ago Phase 3 Study Supports Pembrolizumab Plus Lenvatinib as Standard of Care in Patients With Advanced Endometrial Cancer Who Received Prior Platinum Therapy - about 1 year ago
4	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Incyte’s checkpoint inhibitor staves off disease progression in anal cancer trial - 2 months ago STAT+: Results on Novartis prostate cancer therapy could expand its use - about 1 year ago
5	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	New Study Assesses Ifinatamab Deruxtecan for Treatment of Small Cell Lung Cancer - 3 months ago FDA Approves Durvalumab Plus Chemotherapy to Treat Endometrial Cancer - 5 months ago Jazz Pharmaceuticals Submits Biologics License Application for Zanidatamab to Treat Biliary Tract Cancer - 8 months ago Novel Chemotherapy Method Could Decrease Lung Cancer Tumor Size - 9 months ago FDA Approves Irinotecan Liposome for Metastatic Pancreatic Adenocarcinoma - 9 months ago
6	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study - 5 months ago FDA Approves New Frontline Regimen for Aggressive ALL - 8 months ago Non-Covalent BTK Inhibitor Approved for CLL - 12 months ago
7	Mike Hennessy Jr, President and CEO Pharmacy Times Pro middleweight boxer. UK/Ireland. BoxingSports	Navigating Oncology Drug Shortages: Ethical Frameworks and Strategic Management - 5 months ago
8	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical - 6 months ago
9	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Dostarlimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit in Endometrial Cancer - 8 months ago Pembrolizumab, Chemoradiotherapy Meet Overall Survival Endpoint for Cervical Cancer - 8 months ago FDA Approves Enfortumab Vedotin, Pembrolizumab for Treatment of Urothelial Cancer - 11 months ago FDA Approves Capivasertib With Fulvestrant for PIK3CA/ALT1/PTEN Alterations Breast Cancer - about 1 year ago Datopotamab Deruxtecan Demonstrates Improvement in Progression-Free Survival in HR+, HER2- Breast Cancer - about 1 year ago
10	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Black Diamond looks to outwit cancer mutations - 9 months ago

Journalists covering cisplatin